



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/776,333	02/10/2004	Michael Moshman	077350.0136	1725

62965 7590 01/21/2011  
BAKER BOTTS L.L.P.  
30 ROCKEFELLER PLAZA  
44th Floor  
NEW YORK, NY 10112-4498

EXAMINER
----------

MERCIER, MELISSA S

ART UNIT	PAPER NUMBER
----------	--------------

1615

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

01/21/2011

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

DLNYDOCKET@BAKERBOTTS.COM

<b>Office Action Summary</b>	<b>Application No.</b> 10/776,333	<b>Applicant(s)</b> MOSHMAN ET AL.	
	<b>Examiner</b> MELISSA S. MERCIER	<b>Art Unit</b> 1615	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 20 October 2010.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,2 and 4-36 is/are pending in the application.
- 4a) Of the above claim(s) 18 and 19 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-2, 4-17, 20-36 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |                                                                                        |                                                                   |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>10/20/10</u> .                                                | 6) <input type="checkbox"/> Other: _____                          |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 20, 2010 has been entered.

No claim amendments have been submitted. Claims 1-2 and 4-36 remain pending in this application. Claims 18-19 remain withdrawn from consideration. Therefore, claims 1-2, 4-17, and 19-36 remain under prosecution in this application.

### ***Maintained Rejections***

#### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-2, 4-9, 12, 14-17, and 20-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Illum et al. (US Patent 6,387,917) in view of Grebow et al. (US Patent 5,026,825).

Art Unit: 1615

Illum discloses a methane sulphonate salt of morphine and compositions thereof having medicinal uses, particularly for the treatment of pain and adapted for nasal delivery (abstract). Illum discloses the methane sulfonate salt of morphine is commonly termed mesylate (column 2, lines 31-35). The preferred composition comprises aqueous solutions in which the methane sulphonate salt is combined with chitosan to provide an increased absorption of the drug (column 2, lines 61-68). The morphine methane sulphonate liquid formulation will comprise 0.1mg/mL to about 600mg/mL morphine content (column 4, lines 20-24). The formulation may also be incorporate into formulations suitable for oral, buccal, rectal, or vaginal administration (column 4, lines 39-42). Illum's Examples 2-3 discloses a solution for intranasal administration comprising 8g morphine base (monohydrate), to which 2M methane sulphonic acid solution is stirred in, and 25mL of chitosan (column 5, line 33 through column 6, line 21). It is noted in claim 9, that Applicant has identified methane sulfonic acid as an antioxidant. The prior art teaches mixing morphine base monohydrate with methane sulphonic acid in which no additional method steps are performed, (i.e. heating, precipitation), then adding the chitosan solution. Therefore, Applicants is directed to their own specification on page 10-11, in which Applicant has used the same method steps as Illum, and would necessarily result in the conversation of the base monohydrate to the methane sulphonate salt of morphine. Example 2 additionally discloses a weight ratio of morphine (150mg/ml) to chitosan (5mg/ml) is 10:1, thereby meeting the claim limitations. As discussed above, the morphine can also be present in the amount of 0.1mg/ml to 600mg/ml; therefore, the skilled artisan would be able to

Art Unit: 1615

determine the optimal therapeutic benefit by optimizing the morphine to chitosan ratio based on the teachings of Illum.

The pH of the formulation is adjusted to a range of about 4-7 by adding additional methane sulfonic acid solution or an alkali (column 3, lines 36-40).

Illum further discloses the formulation can also contain other ingredients such as buffer systems, pH modifiers, anti-oxidants, stabilizing agents, anti-microbial agents, chelating agents, viscosity-enhancing agents, or other agents generally used in pharmaceutical formulations (column 4, lines 25-29).

While Illum discloses the use of antimicrobial agents, Illum does not disclose the use of benzalkonium chloride, disodium EDTA, sodium benzoate, and combinations thereof.

Grebow discloses an intranasal formulation comprising antimicrobial agents including benzalkonium chloride and disodium EDTA (Examples). They are present in the amount of 0.001-2.0% (w/v) (column 11, lines 55-63).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have incorporated the specific antimicrobial agents of Grebow into the formulation of Illum since Grebow discloses they are suitable for use in nasal inhalant formulations.

Illum does not disclose the molecule to molecule ratio of morphine to chitosan recited in the instant claims. Illum does however disclose the same weight ratios recited in the specification on which would result in the claimed linear absorption rates upon administration. , therefore, it is the position of the Examiner that since Illum discloses

Art Unit: 1615

the same morphine and the same chitosan in the same weight ratios as recited as able to silicate the desired release, it would also meet the limitations of the molecule to molecule ratio, absent a showing of evidence to the contrary.

Furthermore the claims differ from the reference by reciting various concentrations of the active ingredient(s). However, the preparation of various transmucosally compositions having various amounts of the active agent and chitosan polymers is within the level of skill of one having ordinary skill in the art at the time of the invention. It has also been held that the mere selection of proportions and ranges is not patentable absent a showing of criticality. See *In re Russell*, 439 F.2d 1228 169 USPQ 426(CCPA 1971).

### ***Response to Arguments***

Applicant's arguments have been fully considered but they are not persuasive.

Applicant argues:

**\*there is no reasonable expectation of successfully substituting the antimicrobial agents of Grebow into the formulation of Illum.**

The Examiner respectfully disagrees. Illum discloses his nasal formulation can comprise antimicrobial agents. Grebow is relied on for the inclusion of specific, art recognized, antimicrobial agents suitable for use in nasal formulations. The relevance of the aminolevulinic acid to the rejection discussed above is unclear to the Examiner. Clarification of how the antimicrobial agents would be unsuitable for use in other nasal formulations is requested.

Art Unit: 1615

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Illum et al. (US Patent 6,387,917) in view of Grebow et al. (US Patent 5,026,825) and further in view of Tulin-Silver et al. (US 5,508,282).

The teaching of Illum and Grebow are discussed above and applied in the same manner.

Illum discloses the use of antioxidant; however, Illum does not disclose the specific use of ascorbic acid or sodium ascorbate in the amount of 40-70mg/mL.

Tulin discloses compositions and methods for the treatment of rhinosinusitis comprising ascorbic acid in a nasal spray (abstract) in the amount of 15-300mg/ml (Table I).

It would have been obvious to one of ordinary skill to have incorporated the ascorbic acid of Tulin in the formulation of Illum since Tulin discloses it's useful for shortening the symptoms and duration of rhinitis or rhinosinusitis without side effects (column 3, lines 5-8).

Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Illum et al. (US Patent 6,387,917) in view of Grebow et al., (US Patent 5,026,825) and further in view of Santus et al.(US Patent 6,333,044).

The combination of Illum and Grebow are discussed above and applied in the same manner.

Illum and Grebow do not disclose the use of sodium benzoate as an antimicrobial agent.

Santus discloses nasal spray formulations comprising antimicrobial agents. Sodium benzoate is disclosed.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have incorporated the specific antimicrobial agents of Santus into the formulation of Illum and Grebow because it is disclosed as suitable for use in nasal inhalant formulations.

### ***Response to Arguments***

Applicant's arguments have been fully considered but they are not persuasive. Applicant has based the arguments on the combination of Illum and Grebow. Therefore the Examiner will address the rejections together.

#### **Applicant argues:**

**\*The present formulation is stable and the antimicrobial agents and antioxidants are believed to contribute to the stability.**

Applicant has provided no evidence that the antimicrobial agents or antioxidants contribute to the stability of the formulation or that the formulation of Illum is unstable. Applicant has not provided any evidence that the specific use of the claimed antimicrobial agents and antioxidants provide any unexpected results over what would be expected as a functional equivalent.

Furthermore, Illum discloses the use of antimicrobial agents and antioxidants in his formulation. Therefore, the skilled artisan would recognize that the use of antimicrobial and antioxidant agents which can be used in nasal formulation, such as

Art Unit: 1615

those disclosed by Tulin-Silver and Grebow, would be acceptable for inclusion into the formulation of Illum since they are functional equivalents.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S. MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached on 8:00am-4:30pm Mon through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Melissa S Mercier/  
Examiner, Art Unit 1615

/Robert A. Wax/  
Supervisory Patent Examiner, Art  
Unit 1615

Application/Control Number: 10/776,333  
Art Unit: 1615

Page 9